US Patent 9205098 Anti-cancer therapies
Patent 9205098 was granted and assigned to Threshold Pharmaceuticals on December, 2015 by the United States Patent and Trademark Office.
All edits
Edits on 3 Dec, 2023
Golden AI
Edits made to:
Article (+223 characters)
Article
Patent abstract
Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09205098 Anti-cancer therapies US Patent 9205098 Anti-cancer therapies
Infobox
Patent Number
092050980
Patent Number
92050980
Edits on 30 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
092050980
Date of Patent
December 8, 2015
0Patent Application Number
136587410
Date Filed
October 23, 2012
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09205098 Anti-cancer therapies
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09205098
Date of patent
December 8, 2015
Patent application number
13658741
Date Filed
October 23, 2012
Patent primary examiner
Find more entities like US Patent 9205098 Anti-cancer therapies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.